Drug-induced neutropenia and agranulocytosis represent serious adverse haematological conditions arising from the administration of a variety of therapeutic agents. These conditions involve a marked ...

Ryzneuta is a non-pegylated granulocyte colony-stimulating factor. The Food and Drug Administration (FDA) has approved Ryzneuta ® (efbemalenograstim alfa-vuxw), a leukocyte growth factor, to decrease ...

The US Food and Drug Administration (FDA) approved a new colony-stimulating factor, efbemalenograstim alfa (Ryzneuta, Evive Biotech), to decrease the incidence of infection, as manifested by febrile ...

Objective: To systematically evaluate the literature to determine whether vancomycin-induced neutropenia is dose- or duration-related and provide clinicians with feasible treatment alternatives. Data ...

Autoimmune neutropenia is a multifaceted condition in which the immune system erroneously produces autoantibodies that target neutrophils, leading to their premature destruction and a consequential ...